We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today. The company’s shares closed last ...

MERCK & CO INC (MRK) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.